The role of glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 5, 2012, Pages 391-399

  Smolarczyk, Ryszard ^a   Cichoń, Tomasz ^a   Matuszczak, Sybilla ^a   Mitrus, Iwona ^a   Lesiak, Marta ^b   Kobusińska, Magdalena ^a   Kamysz, Wojciech ^c   Jarosz, Magdalena ^a   Sieroń, Aleksander ^b   Szala, Stanisław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Anticancer peptide; Glycyrrhizin; Hmgb1; Necrosis; Tumor therapy

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; PEPTIDE CAMEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; MALE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN FUNCTION; RAT; SEQUENCE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL PROLIFERATION; ENDOTHELIAL CELLS; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MELANOMA, EXPERIMENTAL; MICE; NECROSIS; NIH 3T3 CELLS; PEPTIDES; RATS; SAPONINS;

EID: 84866631280     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0183-0     Document Type: Article

References (28)

1. Campana L, Bosurgi L, Rovere-Querini P (2008) HMGB1: a twoheaded signal regulating tumor progression and immunity. Curr Opin Immunol 20:518-523
2. Coffelt SB, Scandurro AB (2008) Tumors sound the alarmin (s). Cancer Res 68:6482-6485
3. Ellerman JE, Brown CK, de Vera M et al (2007) Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 13:2836-2848 (Pubitemid 46850704)
4. Gauley J, Pisetsky DS (2009) The translocation of HMGB1 during cell activation and cell death. Autoimmunity 42:299-301
5. Girard JP (2007) A direct inhibitor of HMGB1 cytokine. Chem Biol 14:345-347
6. Hanahan D, Weinberg RA (2011) The hallmarks of cancer: the next generation. Cell 144:646-674
7. Klune JR, Dhupar R, Cardinal J et al (2008) HMGB1: endogenous danger signaling. Mol Med 14:476-484
8. Lamore SD, Cabello CM, Wondrak GT (2010) HMGB1-directed drug discovery targeting cutaneous inflammatory dysregulation. Curr Drug Metab 11:250-265
9. Le Bitoux MA, Stamenkovic I (2008) Tumor-host interactions: the role of inflammation. Histochem Cell Biol 130:1079-1090
10. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342 (Pubitemid 40516158)
11. Mitola S, Belleri M, Urbinati C et al (2006) Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176:12-15 (Pubitemid 43023243)
12. Mollica L, De Marchis F, Spitaleri A et al (2007) GR binds to highmobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14:431-441 (Pubitemid 46617319)
13. Nicosia RF, Ottinetti A (1990) Growth of microvessels in serum-free matrix culture of rat aorta. Lab Invest 63:115-122
14. Palumbo R, Sampaolesi M, De Marchis F et al (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164:441-449 (Pubitemid 38174771)
15. Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9:285-293
16. Raucci A, Palumbo R, Bianchi ME (2007) HMGB1: a signal of necrosis. Autoimmunity 40:285-289 (Pubitemid 46845522)
17. Rovere-Querini P, Capobianco A, Scaffidi P et al (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5:825-830 (Pubitemid 39199174)
18. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195 (Pubitemid 34773774)
19. Schlueter C, Weber H, Meyer B et al (2005) Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166:1259-1263 (Pubitemid 40524448)
20. Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367-388
21. Smolarczyk R, Cichoń T, Szala S (2009) Peptides: a new class of anticancer drugs. Postepy Hig Med Dosw 63:360-368
22. Smolarczyk R, Cichoń T, Kamysz W et al (2010) Anticancer effects of CAMEL peptide. Lab Invest 90:940-952
23. Srikrishna G, Freeze HH (2009) Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11:615-628
24. Tang D, Kang R, Zeh HJ 3rd et al (2010) High-mobility group box 1and cancer. Biochim Biophys Acta 1799:131-140
25. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E et al (2012) Tumor angiogenesis is enforced by autocrine regulation of highmobility group box 1. Oncogene. doi:10.1038/onc.2012.49
26. Yang H, Tracey KJ (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799:149-156
27. Yang H, Wang H, Czura CJ et al (2005) The cytokine activity of HMGB1. J Leukoc Biol 78:1-8 (Pubitemid 40979937)
28. Zhu S, Li W, Ward MF et al (2010) High mobility group box 1 protein as a potential drug target for infection-and injury-elicited inflammation. Inflamm Allergy Drug Targets 9:60-72